A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Conditions
Gynecologic Cancers · Platinum-Sensitive Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer (PSOC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Holy Name Medical Center /ID# 279017, Teaneck, New Jersey, United States
University of Cincinnati Medical Center. /ID# 278925, Cincinnati, Ohio, United States
OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City, Oklahoma, United States
Providence Portland Medical Center /ID# 277727, Portland, Oregon, United States
Women & Infants Hospital /ID# 277930, Providence, Rhode Island, United States
SCRI Oncology Partners /ID# 279733, Nashville, Tennessee, United States
Texas Oncology-Austin North /ID# 279958, Austin, Texas, United States
Next Virginia /ID# 279684, Fairfax, Virginia, United States
Rabin Medical Center /ID# 279142, Petah Tikva, Central District, Israel
The Chaim Sheba Medical Center /ID# 275997, Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 275852, Tel Aviv, Tel Aviv, Israel
Rambam Health Care Campus- Haifa /ID# 276004, Haifa, Israel
Shaare Zedek Medical Center /ID# 275854, Jerusalem, Israel
Hyogo Cancer Center /ID# 276940, Akashi-shi, Hyōgo, Japan
National Cancer Center Hospital /ID# 276715, Chuo-Ku, Tokyo, Japan
The Cancer Institute Hospital Of JFCR /ID# 276711, Koto-ku, Tokyo, Japan
Study leads
ABBVIE INC.
Study Director
AbbVie